Gordon Rustin
Gordon Rustin
Professor of Cancer Therapy
Verified email at
Cited by
Cited by
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations
AR Padhani, G Liu, D Mu-Koh, TL Chenevert, HC Thoeny, T Takahara, ...
Neoplasia 11 (2), 102-125, 2009
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ...
New England Journal of Medicine 366 (15), 1382-1392, 2012
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised …
J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ...
The lancet oncology 15 (8), 852-861, 2014
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS)
AK Kakkar, MN Levine, Z Kadziola, NR Lemoine, V Low, HK Patel, ...
Journal of Clinical Oncology 22 (10), 1944-1948, 2004
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ...
The Lancet Oncology 16 (8), 928-936, 2015
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
GJS Rustin, MEL Van Der Burg, CL Griffin, D Guthrie, A Lamont, ...
The Lancet 376 (9747), 1155-1163, 2010
Phase i trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)
ES Newlands, GRP Blackledge, JA Slack, GJ Rustin, DB Smith, NS Stuart, ...
British journal of cancer 65 (2), 287-291, 1992
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)
GJS Rustin, I Vergote, E Eisenhauer, E Pujade-Lauraine, M Quinn, ...
International Journal of Gynecologic Cancer 21 (2), 2011
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial
RTD Oliver, MD Mason, GM Mead, H von der Maase, GJS Rustin, JK Joffe, ...
The Lancet 366 (9482), 293-300, 2005
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
MO Leach, KM Brindle, JL Evelhoch, JR Griffiths, MR Horsman, A Jackson, ...
British journal of cancer 92 (9), 1599-1610, 2005
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG …
A Du Bois, M Quinn, T Thigpen, J Vermorken, E Avall-Lundqvist, ...
Annals of oncology 16, viii7-viii12, 2005
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo …
JA Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ...
The lancet oncology 17 (11), 1579-1589, 2016
Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.
GJ Rustin, AE Nelstrop, P McClean, MF Brady, WP McGuire, WJ Hoskins, ...
Journal of Clinical Oncology 14 (5), 1545-1551, 1996
Role of tumour markers in monitoring epithelial ovarian cancer
T Meyer, GJS Rustin
British journal of cancer 82 (9), 1535-1538, 2000
CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use
MJ DUFFY, JM BONFRER, J Kulpa, GJS Rustin, G Soletormos, GC Torre, ...
International Journal of Gynecologic Cancer 15 (5), 2005
Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study
GJS Rustin, AE Nelstrop, MK Tuxen, HE Lambert
Annals of oncology 7 (4), 361-364, 1996
Reproducibility of dynamic contrast‐enhanced MRI in human muscle and tumours: comparison of quantitative and semi‐quantitative analysis
SM Galbraith, MA Lodge, NJ Taylor, GJS Rustin, S Bentzen, JJ Stirling, ...
NMR in Biomedicine: An International Journal Devoted to the Development and …, 2002
Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging
SM Galbraith, RJ Maxwell, MA Lodge, GM Tozer, J Wilson, NJ Taylor, ...
Journal of clinical oncology 21 (15), 2831-2842, 2003
Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results
GJS Rustin, SM Galbraith, H Anderson, M Stratford, LK Folkes, L Sena, ...
Journal of clinical oncology 21 (15), 2815-2822, 2003
EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients.
M Bower, ES Newlands, L Holden, D Short, C Brock, GJ Rustin, ...
Journal of Clinical Oncology 15 (7), 2636-2643, 1997
The system can't perform the operation now. Try again later.
Articles 1–20